Financial Policy Issues for HIV Pre-Exposure Prophylaxis: Cost and Access to Insurance
- 31 January 2013
- journal article
- review article
- Published by Elsevier BV in American Journal of Preventive Medicine
- Vol. 44 (1), S125-S128
- https://doi.org/10.1016/j.amepre.2012.09.039
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San FranciscoPLOS ONE, 2011
- Contemporary costs of HIV healthcare in the HAART eraAIDS, 2010
- HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost‐EffectivenessClinical Infectious Diseases, 2009
- Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectivenessAIDS, 2008
- Costs associated with combination antiretroviral therapy in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2004
- Barriers to care among persons living with HIV/AIDS in urban and rural areasAIDS Care, 1998